DC vaccine silencing PD-L1

A dendritic cell (DC) vaccine silencing programmed death ligand 1 (PD-L1) is an investigational immunotherapy in which autologous or allogeneic dendritic cells are engineered ex vivo to reduce or silence the expression of PD-L1, typically using small interfering RNA (siRNA) or other gene-silencing technologies. The rationale is that by knocking down PD-L1 on the surface of DCs, their ability to activate T cells and prime anti-tumor immune responses is enhanced because they no longer deliver inhibitory signals through the interaction of their own PD-L1 with T-cell programmed death-1 (PD-1). This approach aims to overcome tumor-induced immune suppression and improve the efficacy of cancer vaccines. Preclinical studies have shown that such vaccines can induce stronger cytotoxic T lymphocyte responses and increase production of pro-inflammatory cytokines like IL-12 relative to IL-10. Early clinical research has focused on hematologic malignancies and solid tumors[2][4][3].

Other names

PD-L1-silenced dendritic cell vaccinePD-L-1-silenced dendritic cell vaccinePD-L 1-silenced dendritic cell vaccinePD-L1-silenced DC vaccinePD-L-1-silenced DC vaccinePD-L 1-silenced DC vaccinedendritic cell-based cancer immunotherapy with PD-L1 knockdown